Biote

Biote Revenue per Share

The Revenue per Share of Biote (BTMD) as of Nov 3, 2026 is 6.24 USD. In the previous year, Revenue per Share was 5.29 USD — a change of 17.92% (higher).

Revenue per Share

6.24USD

YoY

17.92%

Last updated:

Revenue per Share of Biote is 2025 6.24 USD. Revenue per Share of Biote was 2024 5.29 USD. It decreases by 17.92% higher compared to the previous year.

The Biote Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2023
6.14 USD
Jan 1, 2024
5.29 USD
Jan 1, 2025
6.24 USD
Jan 1, 2026 (e)
3.90 USD
Jan 1, 2027 (e)
4.11 USD
Jan 1, 2028 (e)
4.31 USD
Jan 1, 2029 (e)
4.58 USD
Jan 1, 2030 (e)
4.84 USD
The Biote Revenue per Share history
YEARRevenue per ShareYoY
est4.84USD+5.74%
est4.58USD+6.09%
est4.31USD+5.00%
est4.11USD+5.40%
est3.90USD-37.48%
6.24USD+17.92%
5.29USD-13.94%
6.14USD-67.58%
18.95USD+2,408.71%
0.76USD-95.09%
15.39USD+300.59%
3.84USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote Stock analysis

What does Biote do? biote Corp. generates revenue through its Biote Method platform, which offers certified practitioners comprehensive tools for hormone optimization. The platform includes education, training, certification, practice management software, inventory management software, and marketing support. Biote also sells a branded line of dietary supplements directly to practitioners and patients. The company's primary customers are Biote-certified practitioners who use the platform to build and manage hormone optimization programs, while the dietary supplements target patients seeking complementary wellness solutions. The Biote Method's proprietary clinical decision support (CDS) system helps physicians personalize patient dosing, enhancing the value proposition for practitioners. By providing end-to-end solutions—from certification to software tools—biote Corp. creates recurring revenue streams through ongoing platform usage and product sales. The company's focus on hormone replacement therapy (HRT) products and practitioner support positions it within the specialized healthcare market segment for bio-identical hormone therapy. biote Corp. differentiates itself through its woman-led structure and comprehensive approach to hormone optimization. The firm's revenue model relies on both service-based offerings for practitioners and direct sales of branded supplements. This dual approach ensures consistent income from certified practitioners who depend on the platform for practice management and from patients purchasing the supplement line as part of their wellness regimen. Biote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biote stock

Revenue per Share of Biote is 6.24 USD in 2025.

Revenue per Share of Biote changed from 5.29 USD to 6.24 USD, representing a 17.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Biote since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biote

All Key Metrics — Biote